Technology Bundle ID: TAB-2507

Methods and Composition for Identification of Variants of JC Virus DNA; An Etiologic Agent for Progressive Multifocal Leukoencephalopathy (PML)

Request More Info
Primary Inventors: 
Eugene Major (NINDS)
Caroline Ryschkewitsch (NINDS)
Therapeutic Area: 
Infectious Disease
Development Status: 
  • Clinical
  • In vitro data available
  • In vivo data available (human)
Institute or Center: 

JC Virus causes a fatal disease in the brain called progressive multifocal leukoencephalopathy (PML) that occurs in many patients with immunocompromised conditions. The finding of JCV DNA in the patients with neurological symptoms of PML is a diagnostic criterion and is needed to confirm the diagnosis of PML to rule out other neurological conditions. Certain JC virus variants are known to have a greater association with PML. For example, "Prototype" JC virus is far more pathogenic than "Archetype" JC virus.

This invention claims novel assays for identifying Archetype and/or Prototype JC virus by detecting the presence or absence of the unique Archetype nucleic acid sequence in the non-coding regulatory region of JC virus. While the sequences of Archetype and Prototype JC virus are known, these are the first assays that allow discrimination between Prototype and Archetype JC virus in a simple assay without the need for DNA sequencing. The identification of a JC virus as a prototype can lead to early treatment of infected individuals.

  • JCV diagnostic kits.
  • JCV diagnostics.
  • DNA sequencing not required.
  • Single assay format using same template to identify prototype and archetype with 10c/ml sensitivity.


PCT Application PCT/US2013/046158
Filed on 2013-06-17
US Application 61/661,289
Filed on 2012-06-18
US Pat 9,631,243

Issued 2017-04-25

Research Material — Patent protection is not being pursued for this technology.


Perkins MR, et al.
PMID 23144619


Jan 11, 2013

Data Source: